Pyrimidine Derivatives as ALK Kinase Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds that effectively inhibit Anaplastic Lymphoma Kinase (ALK) with improved potency, stability, selectivity, toxicity, and pharmacokinetics properties to treat ALK-positive malignancies, as current treatments are inadequate in addressing the aberrant expression of ALK in tumors such as neuroblastomas and glioblastomas.
Innovation Solution
Development of novel pyrimidine derivatives and their pharmaceutical compositions, which act as potent ALK inhibitors, modulating the kinase activity and inhibiting the growth of ALK-positive cells, including NPM-ALK expressing BaF3 cells and human KARPAS-299 lymphoma cells, with IC50 values ranging from less than 1 nM to 10 µM.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for ALK-positive malignancies, then treatment simplicity is maintained, but therapeutic efficacy and selectivity are insufficient
Solution Approach 1:
The patent modifies molecular parameters of the pyrimidine compound structure (formula I) to optimize ALK inhibition potency while maintaining pharmacokinetic properties. By systematically varying substituents R1-R6 and parameters m-p, the invention achieves enhanced therapeutic efficacy through precise molecular parameter optimization without complicating the treatment regimen.
2Reliability
If pyrimidine derivatives with high potency are developed, then ALK inhibition effectiveness is improved, but molecular complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups at particular positions (R1-R6) of the pyrimidine core structure. Each substituent is strategically placed to enhance ALK binding affinity at critical interaction points while maintaining overall molecular simplicity. This localized optimization allows high potency without proportionally increasing global molecular complexity.
Solution Approach 2:
The pyrimidine derivatives represent composite molecular structures combining a core pyrimidine scaffold with various aromatic and heterocyclic substituents. This composite approach allows the molecule to engage multiple interaction modes with ALK (hydrogen bonding, pi-stacking, hydrophobic interactions) simultaneously, achieving high potency through synergistic effects of different structural components.
3Reliability
If selectivity for ALK is enhanced, then off-target effects are reduced, but compound design constraints increase
Solution Approach 1:
The patent optimizes selectivity by carefully adjusting molecular parameters including substituent types, positions, and stereochemistry. Specific configurations of R1-R6 groups create unique binding geometries that favor ALK over other kinases, while maintaining reasonable synthetic accessibility. The systematic parameter optimization balances selectivity enhancement with design feasibility.
Data Source
Figure 1
AI summary
Disclosed herein are ALK kinase inhibitors, pharmaceutical compositions thereof, and pharmaceutical uses thereof. More particularly disclosed herein are compounds of Formula (I), wherein each substituent of Formula (I) is defined as in the description.